Close
CDMO Safety Testing 2026
Novotech

ChargePoint Technology launches new robotic solution to help transform the future of GMP manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

eschbach Unveils Seqonis Intelligent Operations Platform

eschbach has renamed its flagship enterprise software platform, Shiftconnector,...

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.
- Advertisement -

ChargePoint Technology, a powder and liquid transfer specialist, has announced the launch of a new robotic material handling solution aimed at increasing safety and efficiency in solid dosage drug manufacturing.

The new robotics solution will improve efficiency for manufacturers looking to automate and update their production processes to meet future demand for delivering life-saving drug products to market. This could be revamping portions of existing lines to create semi-continuous cells or developing fully autonomous manufacturing for the more advanced facilities of tomorrow.

The solution will help prevent potential risks associated with manual intervention by eliminating ergonomic and manual handling concerns as well as reducing the risk of cross contamination from personnel.

Combining new PuroGrip, PuroVaso containers and the ChargePoint SBV, the robotic approach will allow manufacturers to upgrade their manufacturing practices by creating a handling system that can be deployed quickly from pre-engineered and off the shelf components

The robotic PuroGrip has been developed to create a seamless connection between robotic arms used in pharmaceutical process lines and ChargePointโ€™s range of lightweight PuroVaso containers. The PuroGrip will be used to effortlessly dock PuroVaso containers into ChargePointโ€™s automated Split Butterfly Valve to create a contained solution for material transfer.

Chris Eccles, CEO of ChargePoint Technology, commented on the news: โ€œContained robotic powder handling is the future of the industry. Recent reports have found that the pharmaceutical robots industry is expected to rise at a CAGR of 6.7% over the next 10 years (1) and we have already seen many of our customers turning to us for a solution to advance their current production processes.

โ€œWe understand how important speed, quality and safety is to our customers and we will continue to evolve our solutions to provide our customers with the best technology to meet their manufacturing needsโ€.

ChargePoint Technology plans to unveil the robotic solution at ACHEMA in Frankfurt (10-14th June) and the PuroGrip will also be displayed in ChargePointโ€™s new facility in Liverpool for demonstration and testing purposes.

ChargePoint Technology offers containment and aseptic transfer valves, single-use and fluid storage and management solutions that are essential for the safe transfer of powders and liquids during pharmaceutical and biopharmaceutical manufacturing.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

eschbach Unveils Seqonis Intelligent Operations Platform

eschbach has renamed its flagship enterprise software platform, Shiftconnector,...

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป